161 related articles for article (PubMed ID: 35157764)
1. Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomas.
Przystal JM; Cianciolo Cosentino C; Yadavilli S; Zhang J; Laternser S; Bonner ER; Prasad R; Dawood AA; Lobeto N; Chin Chong W; Biery MC; Myers C; Olson JM; Panditharatna E; Kritzer B; Mourabit S; Vitanza NA; Filbin MG; de Iuliis GN; Dun MD; Koschmann C; Cain JE; Grotzer MA; Waszak SM; Mueller S; Nazarian J
Neuro Oncol; 2022 Sep; 24(9):1438-1451. PubMed ID: 35157764
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212.
Wagner J; Kline CL; Ralff MD; Lev A; Lulla A; Zhou L; Olson GL; Nallaganchu BR; Benes CH; Allen JE; Prabhu VV; Stogniew M; Oster W; El-Deiry WS
Cell Cycle; 2017 Oct; 16(19):1790-1799. PubMed ID: 28489985
[TBL] [Abstract][Full Text] [Related]
3. Potent preclinical sensitivity to imipridone-based combination therapies in oncohistone H3K27M-mutant diffuse intrinsic pontine glioma is associated with induction of the integrated stress response, TRAIL death receptor DR5, reduced ClpX and apoptosis.
Borsuk R; Zhou L; Chang WI; Zhang Y; Sharma A; Prabhu VV; Tapinos N; Lulla RR; El-Deiry WS
Am J Cancer Res; 2021; 11(9):4607-4623. PubMed ID: 34659909
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of imipridones in targeting mitochondrial metabolism in cancer cells.
Bonner ER; Waszak SM; Grotzer MA; Mueller S; Nazarian J
Neuro Oncol; 2021 Apr; 23(4):542-556. PubMed ID: 33336683
[TBL] [Abstract][Full Text] [Related]
5. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.
Chi AS; Tarapore RS; Hall MD; Shonka N; Gardner S; Umemura Y; Sumrall A; Khatib Z; Mueller S; Kline C; Zaky W; Khatua S; Weathers SP; Odia Y; Niazi TN; Daghistani D; Cherrick I; Korones D; Karajannis MA; Kong XT; Minturn J; Waanders A; Arillaga-Romany I; Batchelor T; Wen PY; Merdinger K; Schalop L; Stogniew M; Allen JE; Oster W; Mehta MP
J Neurooncol; 2019 Oct; 145(1):97-105. PubMed ID: 31456142
[TBL] [Abstract][Full Text] [Related]
6. The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models.
de la Nava D; Ausejo-Mauleon I; Laspidea V; Gonzalez-Huarriz M; Lacalle A; Casares N; Zalacain M; Marrodan L; García-Moure M; Ochoa MC; Tallon-Cobos AC; Hernandez-Osuna R; Marco-Sanz J; Dhandapani L; Hervás-Corpión I; Becher OJ; Nazarian J; Mueller S; Phoenix TN; van der Lugt J; Hernaez M; Guruceaga E; Koschmann C; Venneti S; Allen JE; Dun MD; Fueyo J; Gomez-Manzano C; Gállego Pérez-Larraya J; Patiño-García A; Labiano S; Alonso MM
Neuro Oncol; 2024 Mar; ():. PubMed ID: 38554031
[TBL] [Abstract][Full Text] [Related]
7. ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma.
Jackson ER; Duchatel RJ; Staudt DE; Persson ML; Mannan A; Yadavilli S; Parackal S; Game S; Chong WC; Jayasekara WSN; Grand ML; Kearney PS; Douglas AM; Findlay IJ; Germon ZP; McEwen HP; Beitaki TS; Patabendige A; Skerrett-Byrne DA; Nixon B; Smith ND; Day B; Manoharan N; Nagabushan S; Hansford JR; Govender D; McCowage GB; Firestein R; Howlett M; Endersby R; Gottardo NG; Alvaro F; Waszak SM; Larsen MR; Colino-Sanguino Y; Valdes-Mora F; Rakotomalala A; Meignan S; Pasquier E; André N; Hulleman E; Eisenstat DD; Vitanza NA; Nazarian J; Koschmann C; Mueller S; Cain JE; Dun MD
Cancer Res; 2023 May; ():OF1-OF17. PubMed ID: 37195023
[TBL] [Abstract][Full Text] [Related]
8. ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma.
Jackson ER; Duchatel RJ; Staudt DE; Persson ML; Mannan A; Yadavilli S; Parackal S; Game S; Chong WC; Jayasekara WSN; Le Grand M; Kearney PS; Douglas AM; Findlay IJ; Germon ZP; McEwen HP; Beitaki TS; Patabendige A; Skerrett-Byrne DA; Nixon B; Smith ND; Day B; Manoharan N; Nagabushan S; Hansford JR; Govender D; McCowage GB; Firestein R; Howlett M; Endersby R; Gottardo NG; Alvaro F; Waszak SM; Larsen MR; Colino-Sanguino Y; Valdés-Mora F; Rakotomalala A; Meignan S; Pasquier E; Andre N; Hulleman E; Eisenstat DD; Vitanza NA; Nazarian J; Koschmann C; Mueller S; Cain JE; Dun MD
Cancer Res; 2023 May; 83(14):2421-37. PubMed ID: 37145169
[TBL] [Abstract][Full Text] [Related]
9. A review of current therapeutics targeting the mitochondrial protease ClpP in diffuse midline glioma, H3 K27-altered.
Jackson ER; Persson ML; Fish CJ; Findlay IJ; Mueller S; Nazarian J; Hulleman E; van der Lugt J; Duchatel RJ; Dun MD
Neuro Oncol; 2024 May; 26(Supplement_2):S136-S154. PubMed ID: 37589388
[TBL] [Abstract][Full Text] [Related]
10. ONC206 has anti-tumorigenic effects in human ovarian cancer cells and in a transgenic mouse model of high-grade serous ovarian cancer.
Tucker K; Yin Y; Staley SA; Zhao Z; Fang Z; Fan Y; Zhang X; Suo H; Sun W; Prabhu VV; Allen JE; Zhou C; Bae-Jump VL
Am J Cancer Res; 2022; 12(2):521-536. PubMed ID: 35261784
[TBL] [Abstract][Full Text] [Related]
11. Highly potent dopamine receptor D2 antagonist ONC206 demonstrates anti-tumorigenic activity in endometrial cancer.
Staley A; Tucker K; Yin Y; Zhang X; Fan Y; Zhang Y; Fang Z; Sun W; Suo H; Zhao X; Zhao Z; Prabhu VV; Allen JE; Zhou C; Bae-Jump VL
Am J Cancer Res; 2021; 11(11):5374-5387. PubMed ID: 34873466
[TBL] [Abstract][Full Text] [Related]
12. ONC206, an Imipridone Derivative, Induces Cell Death Through Activation of the Integrated Stress Response in Serous Endometrial Cancer
Zhang Y; Huang Y; Yin Y; Fan Y; Sun W; Zhao X; Tucker K; Staley A; Paraghamian S; Hawkins G; Prabhu V; Allen JE; Zhou C; Bae-Jump V
Front Oncol; 2020; 10():577141. PubMed ID: 33194693
[TBL] [Abstract][Full Text] [Related]
13. Mitochondrial Protease ClpP is a Target for the Anticancer Compounds ONC201 and Related Analogues.
Graves PR; Aponte-Collazo LJ; Fennell EMJ; Graves AC; Hale AE; Dicheva N; Herring LE; Gilbert TSK; East MP; McDonald IM; Lockett MR; Ashamalla H; Moorman NJ; Karanewsky DS; Iwanowicz EJ; Holmuhamedov E; Graves LM
ACS Chem Biol; 2019 May; 14(5):1020-1029. PubMed ID: 31021596
[TBL] [Abstract][Full Text] [Related]
14. Discovery and clinical introduction of first-in-class imipridone ONC201.
Allen JE; Kline CL; Prabhu VV; Wagner J; Ishizawa J; Madhukar N; Lev A; Baumeister M; Zhou L; Lulla A; Stogniew M; Schalop L; Benes C; Kaufman HL; Pottorf RS; Nallaganchu BR; Olson GL; Al-Mulla F; Duvic M; Wu GS; Dicker DT; Talekar MK; Lim B; Elemento O; Oster W; Bertino J; Flaherty K; Wang ML; Borthakur G; Andreeff M; Stein M; El-Deiry WS
Oncotarget; 2016 Nov; 7(45):74380-74392. PubMed ID: 27602582
[TBL] [Abstract][Full Text] [Related]
15. ONC201 and imipridones: Anti-cancer compounds with clinical efficacy.
Prabhu VV; Morrow S; Rahman Kawakibi A; Zhou L; Ralff M; Ray J; Jhaveri A; Ferrarini I; Lee Y; Parker C; Zhang Y; Borsuk R; Chang WI; Honeyman JN; Tavora F; Carneiro B; Raufi A; Huntington K; Carlsen L; Louie A; Safran H; Seyhan AA; Tarapore RS; Schalop L; Stogniew M; Allen JE; Oster W; El-Deiry WS
Neoplasia; 2020 Dec; 22(12):725-744. PubMed ID: 33142238
[TBL] [Abstract][Full Text] [Related]
16. Rational combination platform trial design for children and young adults with diffuse midline glioma: A report from PNOC.
Mueller S; Kline C; Franson A; van der Lugt J; Prados M; Waszak SM; Plasschaert SLA; Molinaro AM; Koschmann C; Nazarian J
Neuro Oncol; 2024 May; 26(Supplement_2):S125-S135. PubMed ID: 38124481
[TBL] [Abstract][Full Text] [Related]
17. Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies.
Prabhu VV; Talekar MK; Lulla AR; Kline CLB; Zhou L; Hall J; Van den Heuvel APJ; Dicker DT; Babar J; Grupp SA; Garnett MJ; McDermott U; Benes CH; Pu JJ; Claxton DF; Khan N; Oster W; Allen JE; El-Deiry WS
Cell Cycle; 2018; 17(4):468-478. PubMed ID: 29157092
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and Antiproliferative Activity of Novel Imipridone-Ferrocene Hybrids with Triazole and Alkyne Linkers.
Czuczi T; Murányi J; Bárány P; Móra I; Borbély A; Csala M; Csámpai A
Pharmaceuticals (Basel); 2022 Apr; 15(4):. PubMed ID: 35455465
[TBL] [Abstract][Full Text] [Related]
19. Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways.
Venneti S; Kawakibi AR; Ji S; Waszak SM; Sweha SR; Mota M; Pun M; Deogharkar A; Chung C; Tarapore RS; Ramage S; Chi A; Wen PY; Arrillaga-Romany I; Batchelor TT; Butowski NA; Sumrall A; Shonka N; Harrison RA; de Groot J; Mehta M; Hall MD; Daghistani D; Cloughesy TF; Ellingson BM; Beccaria K; Varlet P; Kim MM; Umemura Y; Garton H; Franson A; Schwartz J; Jain R; Kachman M; Baum H; Burant CF; Mottl SL; Cartaxo RT; John V; Messinger D; Qin T; Peterson E; Sajjakulnukit P; Ravi K; Waugh A; Walling D; Ding Y; Xia Z; Schwendeman A; Hawes D; Yang F; Judkins AR; Wahl D; Lyssiotis CA; de la Nava D; Alonso MM; Eze A; Spitzer J; Schmidt SV; Duchatel RJ; Dun MD; Cain JE; Jiang L; Stopka SA; Baquer G; Regan MS; Filbin MG; Agar NYR; Zhao L; Kumar-Sinha C; Mody R; Chinnaiyan A; Kurokawa R; Pratt D; Yadav VN; Grill J; Kline C; Mueller S; Resnick A; Nazarian J; Allen JE; Odia Y; Gardner SL; Koschmann C
Cancer Discov; 2023 Nov; 13(11):2370-2393. PubMed ID: 37584601
[TBL] [Abstract][Full Text] [Related]
20. Novel combination of imipridones and histone deacetylase inhibitors demonstrate cytotoxic effect through integrated stress response in pediatric solid tumors.
Chang WI; Honeyman JN; Zhang J; Lin C; Sharma A; Zhou L; Oliveira J; Tapinos N; Lulla RR; Prabhu VV; El-Deiry WS
Am J Cancer Res; 2023; 13(12):6241-6255. PubMed ID: 38187038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
